Hypertension — defined by the 2017 ACC/AHA guidelines as sustained systolic blood pressure ≥130 mmHg or diastolic ≥80 mmHg — affects approximately 122 million American adults (47% of the adult population). It is the single most common diagnosis in primary care, the leading cause of preventable cardiovascular morbidity and mortality, and yet the condition with perhaps the widest gap between available effective treatment and real-world control rates. Data from 2021–2022 National Health and Nutrition Examination Survey (NHANES) shows only 38% of hypertensive American adults have their blood pressure controlled below 130/80 — a deterioration from a peak of 54% controlled in 2013, representing a genuine public health regression in the most critical cardiovascular risk factor.
Why BP Control Has Worsened
Multiple factors converge: the 2017 guideline redefinition from 140/90 to 130/80 mmHg instantly classified an additional 31 million Americans as hypertensive without adding corresponding clinical infrastructure; COVID-19 disrupted 40 million primary care encounters in 2020 alone; medication non-adherence rates are 50–60% at one year for antihypertensive medications (largely asymptomatic, with medication side effects perceived as worse than the "silent killer"); clinical inertia — physicians not intensifying therapy at clearly uncontrolled BP visits — explains an estimated 45% of poor control; and social determinants including food insecurity, housing instability, work stress, and limited healthcare access drive BP variability that eludes medication-only approaches.
SPRINT Trial: The Evidence for Lower Targets
The SPRINT (Systolic Blood Pressure Intervention Trial) — enrolling 9,361 adults at high cardiovascular risk to intensive (<120 mmHg) versus standard (<140 mmHg) SBP targets — demonstrated 25% lower rate of major cardiovascular events and 27% lower all-cause mortality in the intensive treatment arm at 3.3 years. These results, published in 2015, drove the 2017 ACC/AHA guideline revision and re-energized population blood pressure reduction as a priority. For patients meeting SPRINT eligibility criteria (no diabetes, >50 years, cardiovascular risk ≥15%), guidelines recommend targeting SBP <120 mmHg when tolerated.
Team-Based Care and Pharmacy-Led Models
The highest-evidence intervention for improving population-level BP control is pharmacist-led collaborative drug therapy management — in which trained clinical pharmacists independently titrate antihypertensive medications per protocol. A 2020 JAMA meta-analysis found pharmacy-led hypertension management achieved 23.2 mmHg greater SBP reduction than physician-only usual care. Home blood pressure monitoring (HBPM) — with validated devices submitted through patient portals or RPM platforms — enables detection of white coat effect, masked hypertension, and medication timing optimization that single-office readings cannot provide. AHA recommends HBPM for all patients with hypertension diagnosis confirmation and ongoing titration. Healthcare facilities and community health programs managing hypertension at scale should stock validated blood pressure monitoring equipment and ensure availability of home monitoring devices for patient dispensing.
